BIIB · Biogen Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Jul 29, 2026TL;DR. Biogen reported Q2 total revenue of $2.7B, up 3% YoY, and raised full-year 2026 total revenue guidance from a mid-single-digit percentage decrease to a mid-single-digit percentage increase, while updating its full-year non-GAAP diluted EPS range to $12–$13.
- + Raised 2026 total revenue guidance from a mid-single-digit percentage decrease to a mid-single-digit percentage increase.
- + Growth portfolio generated over $1B in Q2, up 24% YoY, now exceeding legacy MS portfolio.
- + Q2 total revenue of $2.7B grew 3% YoY, supported by 10% growth in anti-CD20 royalties/profit share.
- + Lakembi iClick FDA approval enables first-of-its-kind home dosing for both initiation and maintenance in Alzheimer's.
- − Appellus acquisition drives ~$0.85 non-GAAP EPS dilution in 2026 from financing costs.
- − Non-GAAP core OPEX increased 20% YoY in Q2, including ~$95M of post-acquisition Appellus operating expenses.
- − Deurinursen tau program characterized as high-risk, high-reward with no impact on Biogen's growth over the rest of this decade.
- − Q2 GAAP cost of sales impacted by higher amortization and fair value step-ups from SkyClaris (Riata) and Saifovri/Ampavelli (Appellus) acquisitions.
- − Appellus acquisition adds $120–130M impact to other income/expense line in both 2026 and 2027 from interest expense and foregone interest income.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BIIB
this stock
Biogen Inc.
|
$37.48B | +44.2% | +2.2% | — | 4.0% |
|
LLY
ELI LILLY & Co
|
$1.20T | +21.6% | +44.7% | 42.6 | 0.7% |
|
JNJ
Johnson & Johnson
|
$621.22B | +29.3% | +6.0% | 39.2 | 0.9% |
|
ABBV
AbbVie Inc.
|
$500.63B | +24.8% | +8.6% | 80.0 | 0.9% |
|
MRK
Merck & Co., Inc.
|
$369.78B | +39.9% | +1.3% | 119.9 | 1.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BIIB | +7.9% | +12.1% | +35.7% | +12.4% | +44.2% |
| SPY | -1.0% | -0.4% | +6.0% | +0.2% | +12.0% |
| vs SPY | +8.9% | +12.6% | +29.7% | +12.2% | +32.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.